IRadimed (IRMD) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $17.9 million, up 11.2% year-over-year, marking the twelfth consecutive quarter of record revenue, driven by strong demand for IV infusion pump systems.

• Net income for Q2 2024 was $4.9 million, or $0.38 per diluted share, up from $4.2 million, or $0.33 per diluted share, in Q2 2023; non-GAAP diluted EPS was $0.42.

• Gross profit margin reached 78.1%, reflecting lower raw material costs and favorable sales mix.

• U.S. sales grew 20.2% to $15.5 million, while international sales declined 23–25% to $2.4 million.

• Declared a regular quarterly cash dividend of $0.15 per share, payable August 30, 2024.

Financial highlights

• Q2 2024 revenue was $17.9 million (+11.2% YoY); six-month revenue was $35.5 million (+12.3% YoY).

• Device revenue increased 17.2% to $12.7 million, while disposables/services revenue decreased 2–3% to $4.7 million.

• Operating income for Q2 2024 rose 13.4% to $5.6 million.

• Cash from operations was $6.6 million for Q2 2024, and free cash flow was $5.4 million.

• Cash and cash equivalents stood at $48.5 million as of June 30, 2024.

Outlook and guidance

• Q3 2024 revenue expected at $18.0–$18.2 million; GAAP diluted EPS $0.34–$0.37; non-GAAP EPS $0.38–$0.41.

• Full-year 2024 revenue guidance reiterated at $72–$74 million; GAAP EPS $1.37–$1.47; non-GAAP EPS $1.52–$1.62.

• Management expects higher revenue and expenses for the remainder of 2024, with continued dividend payments and facility investment planned.

• 3860 pump revenue expected to remain strong through 2024 and into 2025; new 3870 IV pump revenue anticipated to be modest in Q4 2025, with significant impact in 2026.

• Current cash and cash flow from operations are expected to be sufficient for ongoing requirements for at least the next 12 months.